FDA Proposes to Eliminate “Adequate Provision” Standard for DTC Broadcast Advertising

The Food and Drug Administration (FDA) has signaled its next major step in the Trump administration’s ongoing crackdown on direct-to consumer (DTC) prescription drug advertising. The recently released 2026 Regulatory Plan and Unified Agenda (which provides advance notice on federal regulations agencies are currently developing or reviewing) now includes a proposed rule titled “Transparency in Direct-to-Consumer Advertising” (RIN 0910-AJ14), which would eliminate the “adequate provision” standard from 21 C.F.R. §202.1(e)(1)(i)(B), the regulatory framework that has enabled broadcast DTC advertising for nearly three decades. FDA reports that it expects to issue a Notice of Proposed Rulemaking (NPRM) in December 2026.

This Client Alert analyzes the implications of the proposed rule if issued and practical steps companies should take now.

Background

The adequate provision standard has been part of the prescription drug advertising regulations since 1969 and has served as the practical foundation for DTC broadcast advertising since FDA clarified how to satisfy the standard in 1997. The prescription drug advertising regulations at 21 C.F.R. 202.1 distinguish between print and broadcast advertisements.

Print advertisements must include a brief summary of all necessary information related to side effects and contraindications, which generally contains each of the risk concepts from the product’s approved package labeling. By contrast, advertisements broadcast on television or radio must disclose the product’s major risks — a disclosure called the major statement — but need not include the brief summary if “adequate provision is made for dissemination of the approved or permitted product labeling in connection with the broadcast presentation.”See FDA’s “Guidance for Industry, Consumer-Directed Broadcast Advertisements” (1999), page 3, available at https://www.fda.gov/media/75406/download; see also 21 C.F.R. §202.1(e)(1)(i)(B).

In 1997, FDA issued draft guidance (finalized in 1999) explaining that manufacturers could meet the adequate provision standard by directing viewers to external sources — websites, toll-free numbers, concurrent print advertisements, and healthcare providers — for complete prescribing information.Id.

This 1997/1999 guidance is what made broadcast DTC advertising commercially viable. Prior to it, the requirement to include a full brief summary of all risk information within the advertisement itself made television and radio ads impractical.

The September 2025 Crackdown

On September 9, 2025, President Trump signed a presidential memorandum directing the Department of Health and Human Services (HHS) to “take appropriate action to ensure transparency and accuracy in direct-to-consumer prescription drug advertising, including by increasing the amount of information regarding any risks” and instructing FDA to “take appropriate action to enforce the Federal Food, Drug, and Cosmetic Act’s prescription drug advertising provisions.” (For more details, see this Client Alert.) The same day, FDA, HHS, and the White House announced a coordinated crackdown consisting of three prongs:

• rulemaking to rescind the adequate provision standard;
• enhanced enforcement of existing DTC advertising requirements, including the issuance of over 100 cease-and-desist and warning letters and thousands of compliance letters to drug and biologic sponsors; and
• expanded oversight of prescription drug advertising on social media platforms.

Since September 2025, FDA’s Office of Prescription Drug Promotion (OPDP) has maintained an unprecedented enforcement pace, issuing more than 40 untitled letters in 2025 and 2026, compared to only five in 2024. HHS Secretary Robert F. Kennedy Jr. has been publicly critical of DTC advertising and previously advocated for an outright ban.

General Elements of the Proposed Rule

What We Know

• Scope: The proposed rule, if issued, would remove the adequate provision alternative from 21 C.F.R. §202.1(e)(1)(i)(B), meaning broadcast DTC advertisements could no longer satisfy disclosure obligations by directing consumers to external sources for full prescribing information. Without the adequate provision option, broadcast ads would be required to include a full brief summary of all side effects, contraindications, and effectiveness within the advertisement itself.
• Practical effect: Including a full brief summary of all side effects, contraindications, and effectiveness could render the advertisement so long and unwieldy as to be unworkable and impractical.
• Timeline: The NPRM is targeted for publication in December 2026, after which a public comment period (typically 60–90 days) will follow.
• Stated rationale: HHS has characterized the adequate provision standard as a “loophole” that “has enabled pharmaceutical companies to withhold vital safety information in advertisements,” framing the proposed rule as going “to the core government interests of protecting the public from deception and protecting public health.”See https://www.hhs.gov/press-room/hhs-fda-drug-ad-transparency-fact-sheet.html.

What Remains Uncertain

• Content requirements: The regulatory text has not yet been published and questions remain about the specific form and content requirements for the brief summary in broadcast advertisements. One question is whether FDA will require the same brief summary that is used in print ads or develop a modified standard for broadcast advertisements.
• Social media: It is unclear how such a proposed rule would apply to social media and digital advertising formats, which present unique space and format constraints.
• Transition period: FDA has not addressed transition periods, grandfathering of existing campaigns, or the timeline for compliance once a final rule is issued.

Implications for Companies

If the adequate provision standard is eliminated, the impact on companies marketing FDA-regulated products directly to consumers may be substantial and far-reaching.

Potential End of Broadcast DTC Advertising

The most significant implication is that requiring a full brief summary within broadcast ads could render television and radio DTC advertising commercially non-viable. For many drugs, the brief summary consists of several pages of dense safety information. Including this full content in a 30- or 60-second broadcast spot would be difficult, if not impossible, and extending the length of ads to accommodate the full content would be cost-prohibitive. Hence, this rule change could function as a de facto ban on DTC broadcast advertising for prescription drugs.

Operational and Strategic Impacts

• Advertising strategy overhaul: Companies will need to evaluate whether and how to maintain DTC advertising programs in a post-adequate provision environment, potentially shifting spend to print, digital, and other media channels.
• Impact on digital and social media promotion: Although the proposed rule targets the broadcast advertising regulation, FDA’s broader enforcement posture signals heightened scrutiny of all DTC channels, including marketing conducted in the digital and social media spaces.
• Increased enforcement risk: Regardless of when and whether the rule is finalized, companies are already facing greater enforcement scrutiny of their advertising and promotion activities. OPDP’s dramatically increased letter volume — on pace to exceed 50 letters in 2026 — means that current advertising practices are subject to heightened scrutiny under existing requirements.

Next Steps

Ahead of the expected NPRM in December 2026, companies should consider taking the following steps:

• Document the business impact of the proposed rule, including advertising expenditures, patient reach, and alternative channel analyses. This documentation will be critical for both comments on the NPRM and, potentially, legal challenges.
• Prepare to submit substantive comments on the NPRM when published. Comments should address the legal authority for the rule, the practical impact on patient access to information, the disproportionate burden on smaller manufacturers, and the availability of less restrictive alternatives.
• Engage with industry trade associations that may coordinate comments, fund potential legal challenges, or otherwise advocate collectively.
• Commission economic studies or analyses that quantify the impact of the proposed rule on patient access to medication information and on industry advertising practices, as such data will strengthen both administrative comments and any potential future litigation.

We will continue to monitor the rulemaking process closely. If you have questions about how this proposed rule may affect your DTC advertising programs, or if you wish to discuss comment strategy or potential litigation strategy, please do not hesitate to reach out to your regular contacts at the firm.